Dr Paul Peter Tak of GlaxoSmithKline describes the possible, disadvantageous consequences of a no-deal Brexit.
Current Edition
Current Edition
CDMO Subsection
Insights into the latest developments in CDMO services and manufacturing.
Continue readingInjectables Subsection
Expert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingNasal & Pulmonary Subsection
Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue reading
